Tsfg LLC Sells 149 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

by · The Cerbat Gem

Tsfg LLC lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 61.6% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 93 shares of the medical research company’s stock after selling 149 shares during the period. Tsfg LLC’s holdings in Thermo Fisher Scientific were worth $46,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Bernard Wealth Management Corp. bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $25,000. Pillar Financial Advisors LLC bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $29,000. Ameriflex Group Inc. bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $30,000. Noble Wealth Management PBC bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $35,000. Finally, Cassady Schiller Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 89.2% in the 4th quarter. Cassady Schiller Wealth Management LLC now owns 70 shares of the medical research company’s stock worth $36,000 after purchasing an additional 33 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.1%

Shares of NYSE:TMO opened at $407.67 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. The company’s fifty day simple moving average is $409.74 and its 200 day simple moving average is $483.23. The firm has a market cap of $153.89 billion, a price-to-earnings ratio of 23.91, a PEG ratio of 2.15 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same period in the previous year, the business earned $5.11 EPS. The company’s revenue was up .2% compared to the same quarter last year. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a $0.43 dividend. The ex-dividend date is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.42%. Thermo Fisher Scientific’s payout ratio is currently 10.09%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a report on Thursday, April 24th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, May 21st. Royal Bank Of Canada lowered their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating for the company in a research note on Thursday, April 24th. Argus cut their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Finally, Barclays cut their target price on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an “equal weight” rating on the stock in a report on Tuesday, June 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $604.05.

View Our Latest Research Report on TMO

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).